arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Prelude Therapeutics Inc

PRLD
$4.89 ▲ +0.23 (+4.93%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
9
Health
Poor
Bearish
auto_awesome

Analytical Summary

Prelude Therapeutics Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $403.5M
Dividend Yield
Revenue Growth None
Op. Margin -309.5%
ROIC -18.6%
FCF / Share $-0.26
Trailing P/E
Price / Book 6.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.58M
↓ -18.8%
Net Income Profit after all expenses
$-10.38M
↑ +67.6%
Operating Margin Operating profit as % of sales
-309.5%
↓ -0.6%
FCF / Share Free cash flow per share
$-0.26
↑ +41.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
5
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters